Mesoblast stock(rock)-take March 2024, page-187

That's right. It was Hinrich's patent Interleukins IL-21 and IL-15 that bothered me, and their inflammatory deregulation effects in cancers. Obviously Interleukins being a major component of Remestemcel-L's anti inflammatory cascade....

Have to dust the cobwebs out on this stuff:

https://www.tga.gov.au/sites/default/files/auspar-remestemcel-l-150315.pdf

Anyway, as you guys importantly point out, all that EAP data very reasonably concluded as back in play from your and others excellent understanding of the FDA prcoedures and processes, that lead to that logical deduction. We should all be doing our research, but @stockrock and @imback yourself and others, thanks for the excellent insights - reminds me of a return to the good old days of MSB threads with some very well informed discussion. We waz robbed .